Overview:
Recent advances in the understanding of pathologic mechanisms in myeloproliferative neoplasms (MPNs) have led to opportunities for novel treatments that may improve patient outcomes. As newer therapies are established and novel strategies are evaluated in clinical trials, it will be essential for clinicians to stay up to date on evolving evidence and their implications for clinical practice, including the tailoring of therapy for patients across lines of treatment, navigating changes in therapy, and mitigating and managing treatment-related adverse events to optimize patient care.
This activity will update hematology-oncology health care
professionals with the most recent data from key abstracts presented at major
cancer conferences so that they can assess and apply these findings to their
clinical practice and ultimately improve care for patients with hematologic
malignancies.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Evaluate recent clinical trial data for current and emerging therapies for patients with MPNs
- Select personalized therapeutic strategies for patients with MPNs based on current paradigms and emerging, practice-changing clinical evidence
- Implement appropriate strategies to monitor, mitigate, and manage toxicities associated with therapies for MPNs to improve treatment adherence and patient quality of life
Target Audience:
This educational activity is directed toward academic and community-based oncologists, hematologists, advanced practice providers, oncology nurses, and other health care providers involved in the treatment of patients with MPNs.
John O. Mascarenhas, MD
Director, Center of Excellence in Blood Cancers and
Myeloid Disorders
Professor of Medicine
Icahn School of Medicine at Mount Sinai
The Tisch Cancer Institute
New York, NY
Raajit Rampal, MD
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, NY
Claire Harrison, MD
Professor of Myeloproliferative Neoplasms
Clinical Director
Guy's and St Thomas' NHS Foundation Trust
London, England
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’
Education Resource®, LLC is approved by the California Board of
Registered Nursing, Provider #16669, for 1.5 Contact Hours.